# A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

> **NCT00237939** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 1200 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00237939
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 1200 (—)
- **Last updated:** 2013-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237939, "A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00237939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*